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Background:The hexanucleotide repeat expansion in intron 1 of the C9orf72 gene is rec-
ognized as the most common genetic cause of frontotemporal dementia (FTD). There are
overlapping clinical and pathological characteristics between FTD and Parkinsonism syn-
drome, and some FTD patients may present with Parkinsonism.The aim of this study was to
analyze the hexanucleotide repeat numbers of C9orf72 gene in a mixed Taiwanese cohort
with FTD, Parkinsonism syndrome, Parkinson’s disease (PD), and Alzheimer’s dementia
(AD).
Method:The number of hexanucleotide repeats was estimated in a total of 482 patients
with mixed neurodegenerative disorders and 485 control subjects, using a two-step repeat-
primed polymerase chain reaction-based genotyping strategy. The individual groups of
patients included patients with Parkinsonism syndrome (n=95), familial PD (n=109),
young-onset PD (n=201), FTD (n=9), sporadic AD (n=61), and early-onset AD (n=7).
Results: We did not identify any pathogenic repeats (>30 repeats) of C9orf72 in either
the patients or control subjects. However, we found one young-onset PD patient and
one control subject that each had an intermediate number of repeats (25 and 21 repeats,
respectively).The clinical phenotype of the young-onset PD in this patient was similar to typ-
ical idiopathic PD without additional features, and the patient responded well to levodopa
treatment.
Conclusion:The repeat expansion in C9orf72 is not a common cause of PD, Parkinsonism
syndrome, or dementia in our population. Further studies are needed to investigate the
clinical and biological significance of intermediate repeats in C9orf72.
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INTRODUCTION
A massive expansion of the GGGGCC hexanucleotide repeat in the
intron between non-coding exons 1a and 1b of the chromosome
9 open reading frame 72 (C9orf72) gene was recently found to be
a major genetic cause of familial frontotemporal dementia (FTD)
and amyotrophic lateral sclerosis (ALS) (1, 2). Patients who carry
the repeat expansion have an earlier onset, shorter survival, and
familial aggregation of dementia or other neurodegenerative dis-
orders than patients with normal repeat number of C9orf72 (3). In
addition to FTD and ALS, other features in patients carrying the
C9orf72 mutation can include isolated Parkinsonian movement
disorder, memory impairment, and signs of cerebellar dysfunc-
tion (4). These symptoms tend to accumulate and phenotypes
may converge with disease progression. Most patients eventually
develop some behavioral abnormalities, as well as language and
motor disabilities (5, 6).
Recently, a number of studies have found that Parkinsonism
may precede, coincide, or follow the behavioral or language-
predominant variant of FTD. FTD with Parkinsonism is part
of a growing spectrum of the dementia–Parkinsonism contin-
uum (7–9). The clinical phenotypes include the Parkinsonism
syndrome of progressive supranuclear palsy (PSP), corticobasal
syndrome (CBS), diffuse Lewy body dementia (DLBD), and
typical Parkinson’s disease (PD) (10). The pathological mark-
ers of these phenotypes include TAR DNA-binding protein 43
(TDP-43), phosphorylated tau, and tau-negative but ubiquitin-
positive neuronal inclusions (6, 11). Therefore, given the clini-
cal and pathological overlaps between FTD, Parkinsonism syn-
drome, PD, and Alzheimer’s dementia (AD), the aim of this
study was to determine whether the abnormal C9orf72 hexanu-
cleotide repeat expansions found in FTD patients is also associ-
ated with these other neurodegenerative disorders in a Taiwanese
population.
MATERIALS AND METHODS
SUBJECTS
A total of 482 patients with mixed neurodegenerative disorders
and 485 ethnicity matched control subjects were enrolled in the
study. The individual groups included patients with Parkinson-
ism syndrome (n= 95), familial PD (n= 109), young-onset PD
(age at onset <50 years, n= 201), FTD (n= 9), sporadic late-
onset AD (n= 61), and early-onset AD (age at onset <50 years,
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Table 1 | Demographic data of the enrolled subjects in each disease group.
Subject group Patient number (male/female) Current age (years) Onset age (years)
Parkinsonism syndrome 95 (53/42) 69.1 ± 13.3 59.5 ± 13.6
MSA 51 (26/25) 69.5 ± 12.7 60.1 ± 12.5
PSP 14 (9/5) 69.1 ± 12.9 60.2 ± 12.6
CBS 2 (2/0) 68.9 ± 13.3 57.6 ± 13.8
PDD 17 (10/7) 69.6 ± 13.1 60.2 ± 12.7
DLBD 3 (2/1) 69.9 ± 12.3 59.1 ± 12.8
Parkinsonism with dystonia 6 (3/3) 34.3 ± 13.6 18.7 ± 12.1
Parkinsonism with FTD 2 (1/1) 69.5 ± 7.5 65.3 ± 11.5
Familial PD 109 (57/52) 66.5 ± 12.2 55.6 ± 13.4
Young-onset PD 201 (103/98) 54.3 ± 7.6 42.5 ± 5.2
Dementia 77 (29/48) 58.1 ± 11.4 55.0 ± 4.5
FTD 9 (4/5) 58.0 ± 13.9 53.9 ± 7.8
AD 61 (20/41) 64.1 ± 4.5 55.0 ± 4.5
Early-onset AD 7 (6/1) 50.6 ± 4.2 46.7 ± 3.2
Control subjects 485 (233/252) 60.6 ± 11.9 N.A.
The data are shown as mean± standard deviation.
MSA, multiple system atrophy; PSP, progressive supranuclear palsy; CBS, corticobasal syndrome; PDD, Parkinson’s disease with dementia; DLBD, dementia with
Lewy bodies; FTD, frontotemporal dementia; PD, Parkinson’s disease; AD, Alzheimer’s dementia; N.A., not applicable
Table 2 | Distribution of C9orf72 (GGGGCC) repeat numbers in each disease group and control subjects.
C9orf72 (GGGGCC)
repeat number
Parkinsonism syndrome
(n=190 alleles) n (%)
Familial PD
(n=218 alleles)
n (%)
Young-onset PD
(n=402 alleles)
n (%)
Dementia
(n=154 alleles)
n (%)
Control subjects
(n=970 alleles)
n (%)
1 0 0 0 0 0
2 78 (41.1) 81 (37.2) 165 (41.0) 52 (33.8) 416 (42.9)
3 8 (4.2) 39 (17.9) 13 (3.2) 26 (16.9) 98 (10.1)
4 6 (3.1) 2 (0.9) 0 12 (7.8) 27 (2.8)
5 12 (6.3) 17 (7.8) 41 (10.2) 20 (13.0) 79 (8.2)
6 27 (14.2) 31 (14.2) 59 (14.6) 26 (16.9) 98 (10.1)
7 47 (24.7) 42 (19.2) 100 (24.9) 10 (6.5) 200 (20.6)
8 2 (1.1) 2 (0.9) 6 (1.5) 4 (2.6) 12 (1.2)
9 2 (1.1) 2 (0.9) 10 (2.5) 1 (0.6) 12 (1.2)
10 4 (2.1) 1 (0.5) 6 (1.5) 2 (1.3) 13 (1.4)
11 2 (1.1) 0 0 0 6 (0.6)
12 0 0 0 0 4 (0.4)
13 1 (0.5) 0 0 0 1 (0.1)
14 0 0 0 0 2 (0.2)
15 0 0 1 (0.3) 0 0
16 1 (0.5) 0 0 0 1 (0.1)
17 0 0 0 0 0
18 0 1 (0.5) 0 0 0
19 0 0 0 1 (0.6) 0
20 0 0 0 0 0
21 0 0 0 0 1 (0.1)a
22 0 0 0 0 0
23 0 0 0 0 0
24 0 0 0 0 0
25 0 0 1 (0.3)a 0 0
26 0 0 0 0 0
The data are shown as number (percentage); PD, Parkinson’s disease.
aIntermediate repeats (20–29 repeats).
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FIGURE 1 | Distribution of C9orf72 (C4G2) repeat number in different disease group as compared to control subjects in the current study. The X -axis
represents the estimated repeat number, whereas theY -axis represents the allele frequency. Asterisk indicates intermediate repeats (20–29 repeats).
n= 7). Mutations in the a-synuclein, Parkin,PINK1,DJ-1, LRRK2,
SCA2, SCA3, ATP13A2, and HTRA2 genes were excluded in all
young-onset PD patients (12–16).
Patients with PD were diagnosed using the UK brain bank
diagnosis criteria (17). Patients with FTD were diagnosed using
standard criteria by the Work Group on FTD and Pick’s Disease
(18). AD patients were diagnosed by the NINCDS-ADRDA crite-
ria (19). Unrelated adult volunteers without neurological disease
were recruited as controls from the community and from our hos-
pital. Informed consent was given by all study participants, and the
study was approved by the institutional ethics board committees
of National Taiwan University Hospital.
GENETIC ANALYSIS
DNA was extracted from venous blood using standard protocols
(12). The size of the hexanucleotide repeats in the C9orf72 alle-
les was detected using a two-step repeat-primed polymerase chain
reaction-based genotyping strategy, as previously described (1).
STATISTICAL ANALYSIS
Descriptive statistics were expressed as the mean± the stan-
dard deviation. Differences in the distributions of repeat number
between the individual patient groups and controls were tested
using a two-tailed Mann–Whitney U -test and significance was set
at p= 0.05. Statistical analysis was performed using the STATA,
version 8.0.
RESULTS
The demographic data of all tested subjects are summarized in
Table 1. We used a previously suggested cutoff (>30 repeats) to
distinguish the pathogenic expansion from the normal allele (2).
We did not detect any pathological repeat expansions of C9orf72
in either patients or control subjects.
The range of repeat expansions detected in our participants
was 2–25 units, and the most frequent repeat number was 2
repeats, followed by 6, 7, and 5 repeats. Notably, we found
one young-onset PD patient who had an intermediate num-
ber of 25 repeats, and one control subject who harbored 21
repeats (Table 2). The clinical phenotype of the young-onset
PD in this patient was similar to typical idiopathic PD without
additional features, and the patient responded well to levodopa
treatment. The distribution of the estimated repeat numbers for
each disease group compared to control subjects is presented in
Figure 1.
DISCUSSION
Numerous studies have supported the concept that various neu-
rodegenerative disorders share overlapping clinical, genetic, and
pathologic features. Although the clinical manifestations vary,
some patients with FTD can also show features of PD or Parkin-
sonism syndromes, characterized as PSP, CBS, or DLBD. The
identification of a hexanucleotide repeat expansion in the C9orf72
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gene as a frequent cause of both FTD and ALS suggests a possible
role of this genetic alteration in other dementias or Parkinsonism-
related movement disorders. Herein, we demonstrate that the
C9orf72 repeat expansion is not a common cause of disease for
sporadic AD, FTD, PD, and other related movement disorders in
our population.
Given the relatively small sample size of the individual patient
groups in our series, we cannot definitively exclude the possibil-
ity of a role for the C9orf72 repeat expansion in disease risk. In
parallel with our findings, other recent studies have also shown an
absence of an association between repeat expansion in the C9orf72
gene and disease susceptibility in AD, PD, or related Parkinsonism
syndromes, especially in the Asian population (20–24). We specu-
late that one of the possible reasons why no expansions have been
found in our cases or controls may be due to the fact that carri-
ers of the repeat expansion at C9ORF72 arose from a European
single common founder, implying that expansions are rare in non-
Caucasian populations (25). Another possible reason is that we did
not enroll any patients with ALS and the case number in the FTD
group in small in our present study. Therefore, although the abnor-
mal repeats of C9orf72 gene account for 23–47% of familial FTD
with or without ALS and 4–20% of sporadic ALS (2, 21, 26), our
observation combined with previous findings suggest that varia-
tion in the C9orf72 does not play a major role in the susceptibility
to the wider spectrum of Parkinsonism and dementia syndromes.
Pathological expansion of theC9orf72 hexanucleotide repeats may
be specific to TDP-43 pathology-associated FTD and ALS.
Based on the allele frequencies in cases and controls, the first
studies suggested that expansions with more than 30 repeats
should be considered pathological, while alleles with <20 repeats
are wild type (2). However, subsequent reports have found that
some control subjects may have repeat numbers of 20–30, with
23 being the most frequently reported maximum repeat number
(1, 26). Hence, the contribution of the intermediate-size alleles
(20–29 repeats) to disease pathology needs to be further evaluated.
Notably, recent studies demonstrated that intermediate expan-
sions of the hexanucleotide repeats in C9orf72 may associate with
an increased risk of PD, especially those with repeat numbers over
23 (10, 20, 27–29). In our study, we identified one young-onset
PD patient harboring a repeat number of 25. The mechanism
by which this intermediately expanded repeat number may cause
this disease pathophysiology remains unclear. One hypothesis is
that the expanded hexanucleotide repeat may bind to other RNAs,
resulting in protein sequestration from normal processing and
then decreased protein expression (2, 21). Future functional stud-
ies are necessary to elucidate the role of intermediate repeats in
C9orf72 in neuronal degeneration.
In conclusion, our results do not suggest that an expanded
repeat number in the C9orf72 gene plays a major role in the sus-
ceptibility to the wider spectrum of movement disorders. Further
large-scale studies are required to investigate the clinical and bio-
logical significance of intermediate repeats in the C9orf72 gene in
degenerative neurological disorders.
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